Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer.

ABSTRACT:

Background

Monitoring circulating tumor cells (CTC) has been shown to be prognostic in most solid malignancies. There is no CTC assay in clinical use for lung cancer therapy monitoring due to inconclusive clinical utility data. Limited data has been published outside of the standard CTC enumerations, regarding clinical significance of phenotypic heterogeneity of CTCs in late stage NSCLC and its ability to correlate with treatment outcomes.

Methods

In 81 patients with stage IV NSCLC, multiple timepoints for CTC analysis were collected after initiation of treatment across 139 lines of therapy using single cell high definition diagnostic pathology imaging of all nucleated cells from 362 peripheral blood samples as a liquid biopsy.

Results

We analyzed the subset of 25 pat

SUBMITTER: Shishido SN 

PROVIDER: S-EPMC6714097 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature